Veeva Systems
VEEV
$244.91
-0.76%
Veeva Systems Inc. is a leading provider of cloud-based software solutions specifically designed for the life sciences industry, offering products like Veeva CRM for salesforce automation and Veeva Vault for content and data management. As a dominant player in this niche, Veeva holds a near-monopoly position, serving a wide range of customers from emerging biotech firms to global pharmaceutical giants. The current investor narrative centers on the company's robust growth trajectory, driven by its expansion into new markets and continuous innovation, despite recent stock price volatility. Recent news highlights a 35% decline as a buying opportunity, with analysts optimistic about Veeva's potential to double revenue by 2030, while geopolitical uncertainties and market dynamics add short-term pressure.…
VEEV
Veeva Systems
$244.91
Related headlines
Investment Opinion: Should I buy VEEV Today?
Based on the analysis, Veeva is rated as a 'Buy' with a thesis that its dominant position in life sciences cloud software, strong revenue growth, and improving profitability justify its premium valuation. The analyst consensus is 'Buy' with an average target price of $251.43, implying a modest 1.4% upside, but the high target of $350 suggests significant potential if growth continues. The company's forward PE of 24.72 is attractive relative to its historical range, and its 16.32% revenue growth outpaces the industry average, supporting a positive outlook.
Sign up to view all
VEEV 12-Month Price Forecast
The AI assessment is bullish on Veeva, driven by its strong fundamental performance, attractive valuation relative to growth, and positive analyst sentiment. The company's dominant position in a niche market provides a competitive advantage, and its consistent revenue growth supports the thesis. However, the medium confidence reflects uncertainties around macro conditions and potential competitive threats. The stance would be upgraded to high confidence if revenue growth accelerates above 20% and the stock breaks above its 52-week high, while a downgrade to neutral would occur if growth decelerates below 10% or the stock falls below its 200-day moving average.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Veeva Systems's 12-month outlook, with a consensus price target around $253.57 and implied upside of +3.5% versus the current price.
Average Target
$253.57
0 analysts
Implied Upside
+3.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$165 - $350
Analyst target range
Veeva is covered by 28 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.93 (where 1 is Strong Buy and 5 is Sell). The average price target is $251.43, implying a modest 1.4% upside from the current price of $247.90. The distribution includes 10 Buy ratings, 8 Outperform/Overweight, 7 Hold/Neutral, and 3 Sell/Underperform, indicating a generally bullish but cautious sentiment. The target price range spans from $165.00 (low) to $350.00 (high), with the high target suggesting a 41% upside, likely reflecting expectations of continued strong growth and market expansion, while the low target implies a 33% downside, possibly factoring in competitive risks or a slowdown in the life sciences sector. The wide spread between the low and high targets (185 points) indicates high uncertainty among analysts about Veeva's future performance, which is typical for a growth stock in a specialized niche. Recent ratings from major firms like Evercore ISI, Oppenheimer, and RBC Capital have been reaffirmed, showing stability in analyst sentiment.
Drowning in data?
Find the real signal!
Bulls vs Bears: VEEV Investment Factors
Veeva presents a compelling growth story with dominant market position, strong revenue growth, and solid profitability. The bull case is supported by its near-monopoly in life sciences cloud software, consistent 16%+ revenue growth, and a forward PE that suggests attractive earnings growth. However, the bear case highlights a premium valuation to peers, concentration risk in a single industry, and macro headwinds that could pressure the stock. Currently, the bull case has stronger evidence due to Veeva's fundamental strength and historical undervaluation, but the key tension lies in whether the company can sustain its growth trajectory to justify its premium multiple. If growth decelerates or the life sciences sector faces headwinds, the stock could see significant downside, making the resolution of this growth-versus-valuation debate critical for the investment thesis.
Bullish
- Dominant niche leadership: Veeva holds a near-monopoly in cloud software for life sciences, with products like Veeva CRM and Veeva Vault deeply embedded in the industry. This entrenched position provides a durable competitive moat and high customer switching costs, as evidenced by its consistent revenue growth and high gross margins of 75.5%.
- Strong revenue growth momentum: Revenue grew 16.32% year-over-year in Q1 2027 to $882.95 million, with a compound quarterly growth rate of about 6.9% over the past year. This consistent expansion, driven by both subscription and professional services, underscores robust demand for Veeva's cloud solutions in the life sciences sector.
- Attractive forward valuation: The forward PE of 24.72 is significantly lower than the trailing PE of 36.74, implying expected earnings growth of ~48%. This gap suggests the market is pricing in substantial future profitability, and the current valuation is near the lower end of its historical PE range (24.37-117.15), indicating relative undervaluation.
- Healthy balance sheet and profitability: Veeva boasts a debt-to-equity ratio of just 0.013, a current ratio of 4.89, and strong operating margins of 28.7%. The company generates robust free cash flow of $1.64 billion TTM, providing ample liquidity for reinvestment and resilience against market downturns.
Bearish
- Premium valuation to sector: Veeva trades at a trailing PE of 36.74, a 47% premium to the industry average of 25x. This premium could compress if growth decelerates or if the market shifts toward value stocks, leading to multiple contraction and potential share price decline.
- Geopolitical and macro headwinds: Recent news highlights geopolitical uncertainties, such as Iran tensions, which have pressured growth stocks. Veeva's beta of 0.922 indicates moderate market correlation, but its high valuation makes it vulnerable to risk-off sentiment and sector rotation away from technology.
- Concentration risk in life sciences: Veeva's revenue is heavily concentrated in the life sciences industry, making it susceptible to regulatory changes, patent cliffs, or budget cuts in pharmaceutical R&D. Any downturn in this sector could directly impact demand for Veeva's software, as seen in the 35% stock decline earlier this year.
- Analyst target range wide: The analyst price targets range from $165 to $350, a spread of $185, indicating high uncertainty about future performance. The low target implies a 33% downside from the current price, reflecting concerns about competitive threats or a slowdown in the life sciences market.
VEEV Technical Analysis
Veeva's stock is currently in a strong recovery phase, having rebounded significantly from its 52-week low of $148.05. Over the past year, the stock is down 12.18%, but it has surged 54.77% in the last three months and 34.33% in the last month, indicating a powerful upward momentum. The current price of $247.90 sits at 79.8% of its 52-week range (between $148.05 and $310.50), suggesting the stock is approaching its highs after a substantial recovery, which could signal renewed investor confidence but also potential overextension in the short term.
Beta
0.92
0.92x market volatility
Max Drawdown
-50.5%
Largest decline past year
52-Week Range
$148-$311
Price range past year
Annual Return
-14.5%
Cumulative gain past year
| Period | VEEV Return | S&P 500 |
|---|---|---|
| 1m | +25.9% | +3.6% |
| 3m | +49.0% | +1.5% |
| 6m | +34.6% | +11.7% |
| 1y | -14.5% | +18.7% |
| ytd | +11.6% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VEEV Fundamental Analysis
Veeva's revenue growth remains robust, with the latest quarter (Q1 2027) reporting revenue of $882.95 million, a 16.32% year-over-year increase. This growth is consistent with the trailing quarters, as revenue has steadily risen from $676.18 million in Q2 2025 to $882.95 million, reflecting a compound quarterly growth rate of about 6.9%. The growth is driven by both subscription services (Veeva Commercial Cloud) and professional services, with subscription revenue contributing the majority. This consistent expansion underscores Veeva's strong market position and the increasing adoption of its cloud solutions in the life sciences sector.
Quarterly Revenue
$882948000.0B
2026-04
Revenue YoY Growth
+16.3%
YoY Comparison
Gross Margin
74.7%
Latest Quarter
Free Cash Flow
$1.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VEEV Overvalued?
Given Veeva's positive net income, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 36.74, while the forward PE is 24.72, indicating that the market expects significant earnings growth in the coming year. This gap of 12 points implies a forward earnings growth rate of approximately 48%, which is optimistic but supported by the company's strong fundamentals. Compared to the industry average PE of 25x (based on available data), Veeva trades at a 47% premium, reflecting its superior growth prospects and dominant market position. Historically, Veeva's PE has ranged from 24.37 to 117.15 over the past five years, and the current trailing PE of 36.74 is near the lower end of that range, suggesting that the stock is relatively undervalued compared to its own historical valuation, despite the premium to the sector.
PE
36.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 24x~97x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks: Veeva's financial health is robust, with minimal debt (debt-to-equity of 0.013) and strong liquidity (current ratio of 4.89). However, the company's high valuation (trailing PE of 36.74) leaves little room for error; any earnings miss could trigger a sharp de-rating. Revenue concentration in the life sciences industry is a key operational risk, as a downturn in pharmaceutical R&D spending could directly impact demand. Additionally, while gross margins are high at 75.5%, the company's operating margin of 28.7% could face pressure from increased R&D and sales expenses as it expands into new markets.
FAQ
The key risks of holding Veeva include: 1) Valuation risk, as the stock trades at a premium to peers and could de-rate if growth slows; 2) Concentration risk, with revenue heavily dependent on the life sciences industry, which could be impacted by regulatory changes or budget cuts; 3) Competitive risk from larger tech companies entering the niche; and 4) Macro risk, as high-multiple growth stocks are sensitive to interest rate hikes and geopolitical tensions. The most severe risk is a combination of these factors, which could lead to a 40% downside to the 52-week low of $148.05.
The 12-month forecast for Veeva is cautiously optimistic, with a base case probability of 50% targeting a price range of $240-$280, aligning with the analyst average of $251.43. The bull case (30% probability) targets $280-$350, driven by stronger-than-expected growth, while the bear case (20% probability) targets $165-$200, reflecting potential headwinds. The most likely scenario is the base case, assuming revenue growth remains around 16% and margins stay stable. Investors should monitor quarterly earnings for signs of acceleration or deceleration to adjust their expectations.
Veeva is trading at a trailing PE of 36.74, which is a 47% premium to the industry average of 25x, suggesting it is overvalued relative to peers. However, compared to its own historical PE range of 24.37-117.15, the current multiple is near the lower end, indicating it is undervalued relative to its past. The forward PE of 24.72 implies the market expects significant earnings growth, and the PEG ratio of 1.42 suggests the stock is fairly valued when accounting for growth. Overall, Veeva is not cheap, but its premium is justified by its dominant market position and growth prospects, making it fairly valued for what it offers.
Veeva is a good buy for investors with a long-term horizon and a tolerance for volatility, given its dominant market position and strong growth prospects. The stock offers a modest 1.4% upside to the average analyst target of $251.43, but the high target of $350 implies a potential 41% upside if growth accelerates. However, the stock is trading at a premium valuation (trailing PE of 36.74) and faces risks from market concentration and macro headwinds. For risk-averse investors, it may be prudent to wait for a pullback, while growth-oriented investors could consider initiating a position given the company's fundamental strength.
Veeva is better suited for long-term investment due to its strong growth trajectory, dominant market position, and high margins. The stock's beta of 0.922 indicates moderate volatility, but its recent 54.77% surge in three months shows it can be volatile in the short term. With no dividend, the investment relies on capital appreciation, which is more predictable over a 3-5 year horizon as the company expands its Vault platform and enters new markets. Short-term traders may find opportunities in the stock's swings, but the fundamental thesis supports a long-term holding period of at least 3 years to fully realize the growth potential.